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ABSTRACT 
In this work, we propose for the first time the use of anodic aluminum oxide (AAO) 
nanoporous membranes for in situ monitoring of parathyroid hormone-like hormone 
(PTHLH) secretion in cultured human cells. The biosensing system is based on the 
nanochannels blockage upon immunocomplex formation, which is electrically monitored 
through the voltammetric oxidation of Prussian blue nanoparticles (PBNPs). Models 
evaluated include a neuroblastoma cell line (SK-N-AS) and immortalized keratinocytes 
(HaCaT) as a control of high PTHLH production. The effect of total number of seeded cells 
and incubation time on the secreted PTHLH levels is assessed, finding that secreted PTHLH 
levels range from approximately 60 to 400 ng/mL.  Moreover, our methodology is also 
applied to analyse PTHLH production following PTHLH gene knockdown upon transient cell 
transfection with a specific silencing RNA (siRNA). Given that inhibition of PTHLH 
secretion reduces cell proliferation, survival and invasiveness in a number of tumours, our 
system provides a powerful tool for the preclinical evaluation of therapies that regulate 
PTHLH production. This nanoporous membrane – based sensing technology might be useful 
to monitor the active secretion of other proteins as well, thus contributing to characterize their 
regulation and function. 
 
KEYWORDS: Nanopores/nanochannels, PTHLH, neuroblastoma, cancer cells, 
electrochemical detection. 
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1. INTRODUCTION 
Neuroblastic tumors encompass a heterogeneous group of developmental malignancies 
derived from peripheral nervous system precursor cells. Disseminated cases in infants and 
local-regional, well-differentiated tumors are usually benign. However, metastatic 
neuroblastomas in patients older than 18 months and some local-regional cases display a 
notable capacity to recur and/or become refractory and, unfortunately, there is no therapy 
known to be curative for these patients (Maris, 2010). Moreover, long term survivors suffer 
from secondary effects inflicted by current multimodal therapies (chemotherapy, surgery, 
radiotherapy, autologous bone marrow transplant, differentiating agents and immunotherapy) 
on their normal, developing organs. In this context, there is unmet clinical need for novel 
drugs that specifically target neuroblastoma cells. 
Data gathered over the years by our group are consistent with the hypothesis that the calcium-
sensing receptor (CaSR) exerts tumor-suppressor functions in neuroblastoma (De Torres et 
al., 2009; Casalà et al., 2013; Masvidal et al., 2013; Rodríguez-Hernández et al., 2016; Mateo-
Lozano et al., 2016; Masvidal et al., 2017). In a number of cancers, CaSR activation promotes 
increased secretion of parathyroid hormone-like hormone (PTHLH) (Moseley et al., 1987) a 
protein that exerts relevant roles in the initiation, growth and metastatic processes of several 
tumors (Suva et al., 1987). PTHLH is a secreted factor present in almost all organs and tissues 
of the body. It was first identified in patients with hypercalcemia, being later known its 
involvement in the initiation, survival and progression of primary tumors  (Li et al., 2011; 
Park et al., 2013) as well as in the generation and development of metastases (Iguchi et al., 
1996; Urosevic et al., 2014; Wang et al., 2014; Bilezikian, 1992). 
We first described that PTHLH is also expressed in neuroblastic tumors and upregulated in 
benign, differentiated cases, thus potentially indicating novel functions of this cytokine (De 
Torres et al., 2009). However, the factors that regulate the production and secretion of this 
protein have not been fully characterized, thus making the monitoring of such production of 
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great relevance for i) a better understanding of PTHLH regulation and function and ii) the 
evaluation of novel cancer therapies based on drugs that regulate PTHLH production.  
Radioimmunoassays (RIAs) and immunoradiometric assays (IRMAs) (Fraser et al., 1993; 
Pandian et al., 1992) are the only methods available so far for the detection of PTHLH. 
Implementation of these technologies in laboratories focusing on cell biology is hampered by 
the hazardous and time consuming experimental procedures required, which involve the use 
of sophisticated and expensive equipment and facilities. With the aim of overcoming such 
limitations, we previously reported biosensing systems based on both lateral-flow assays 
(Chamorro-García et al., 2016) and nanochannel technology (Espinoza-Castañeda et al., 
2015) for in vitro quantitation of PTHLH. Furthermore, anodic aluminum oxide (AAO) 
nanoporous membranes have been proposed as outstanding materials for the detection of 
protein biomarkers in complex matrixes, thanks to their ability to act as both filtering and 
sensing platforms. Such sensing is based on nanochannels blockage upon protein recognition, 
which is monitored through the inhibition of an electrical signal (De la Escosura-Muñiz and 
Merkoçi, 2010a; De la Escosura-Muñiz and Merkoçi, 2010b; De la Escosura-Muñiz and 
Merkoçi, 2011; De la Escosura-Muñiz and Merkoçi, 2012; De la Escosura-Muñiz et al., 
2013). In this context, we propose for the first time the use of AAO nanoporous membranes 
for in situ monitoring of parathyroid hormone-like hormone (PTHLH) secretion in cultured 
human cells, as schematized at Figure 1. Also, this secretion is monitored following PTHLH 















Figure 1. Scheme (not in scale) of the biosensing system. HaCaT and SK-N-AS cells are 
cultured onto AAO nanoporous membranes previously modified with anti-PTHLH antibodies. 
Secreted PTHLH is selectively captured and detected through the decrease in the 
electrochemical signal of the Prussian blue nanoparticles used as red-ox indicators (oxidation 
of Prussian blue to Berlin green at approx. +500 mV, analytical signal), due to the 
nanochannels blockage by the immunocomplex formation. 
  
2. EXPERIMENTAL SECTION 
2.1. Cells, proteins and antibodies 
Neuroblastoma cell line SK-N-AS was purchased from the European Collection of Cell Cultures 
and immortalized keratinocytes HaCaT were obtained from the repository at  Institut de Recerca 
Sant Joan de Déu, (Barcelona, Spain). Cells were grown in Roswell Park Memorial Institute 
(RPMI)-1640, supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 
penicillin (100 U/ml) and streptomycin (100 µg/ml), at 37ºC and 5% CO2. Mycoplasma 
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polymerase chain reaction (PCR) tests were routinely performed. Characterization of SK-N-AS 
cells included analysis of MYCN and TP53 status, and authentication by STR profiles (Mateo-
Lozano et al., 2016). 
Parathyroid hormone-like hormone (PTHLH) (SRP4651, human recombinant, expressed in 
E.coli) was purchased from Sigma-Aldrich (Spain). Anti-PTHLH (PC09, 34-53, polyclonal 
antibody developed in rabbit) was purchased from Calbiochem (Spain). Aliquots of this 
antibody were prepared in 0.01 M PBS buffer pH 7.4, containing 5 mM EDC/sulfo-NHS. 
ON-TARGETplusTM Human PTHLH Smart Pool, ON-TARGETplusTM Non-Targeting Pool 
and DharmaFECTTM were purchased from Dharmacon (GELifeSciences). Both siRNAs 
consist on a pool of four siRNA designed to either specifically target PTHLH mRNA 
(siRNA-PTHLH) or for a minimal targeting of human genes (siRNA-NT). 
 
2.2. Chemicals and equipment 
FeCl2·4H2O and K3[Fe(CN)]6 were purchased from Panreac Química SA (Spain). 
Polyvinylpyrrolidone (PVP) (average MW 40 KDa), 3-aminopropyltrimethoxysilane (APS), 
[N -(3-dimethylamino) propyl)]-N-ethylcarbodimide (EDC), sulfo N-hydroxysuccinimide 
(sulfo-NHS), phosphate buffer solutions tablets (PBS) were purchased from Sigma-Aldrich 
(Spain). RPMI-1640 w/o L-glutamine (CE), L-glutamine 200mM (100X), penicillin 
streptomycin solution (100X) and trypsin 0.25%–EDTA solution were purchased from Fisher 
Scientific (Spain). Fetal Bovine Serum EU approved (South Amer.) was purchased from 
Hyclone (Cultek). All chemicals were of analytical grade and used as received. All aqueous 
solutions were prepared in Milli-Q water. Anodized aluminum oxide filter membranes 
(Whatman anodisc AAO, 13 mm diameter, 60 µm thickness, containing 20 nm pores) were 
purchased from Scharlab (Spain). 
Prussian blue nanoparticles (PBNPs) 4 nm-sized were synthetized following the experimental 
procedure described at the Supplementary Material. 
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Thermostatic bath ISOTEMP was purchased from Fisher Scientific (Spain). Incubator NU-
5100E/GCO2 was purchased from Nuaire (USA). A BIOII A/P biosecurity cabinet (from 
Telstar, Spain) was used for cells manipulation. TC Flask 75 cm², Multiple Well Cluster Plate, 
TC-Treated, Sterile, Stripettes individual 25, 10, 5, 2 mL were purchased from Cultek (Spain). 
The homemade screen-printed carbon (SPCEs) used as transducers were prepared following 
the experimental procedure detailed at the Supplementary Material. The experimental set-up 
for the in situ cell culture/electrochemical detection (AAO membranes assembled to SPCEs) 
is detailed at the Supplementary Material. Electrochemical measurements were performed 
with an Autolab 20 (Eco-chemie, The Netherlands) connected to a PC. All the measurements 
were carried out at room temperature with a working volume of 200 µL, which was enough to 
cover the three electrodes contained in the SPCEs connected to the potentiostat by a 
homemade edge connector module. Olympus IX71 (Spain) inverse microscope and Scanning 
Electrochemical Microscopy FEI Quanta 650 FEG ESEM (The Netherlands) were used for 
the optical characterizations. 
 
2.3. Methods 
AAO nanoporous membranes functionalization and in situ cell culturing 
AAO membranes (20 nm-sized pores) functionalization with specific antibodies was 
performed following a previously optimized methodology (De la Escosura-Muñiz and 
Merkoçi, 2010a). Briefly, membranes were first boiled in milli-Q water for 1 h. After drying 
in argon they were immersed in a 5% acetone solution of APS for 1 h. Then they were washed 
in acetone and baked at 120° C for 30 min. After that a 1 mg/mL solution of anti-PTHLH 
antibodies in PBS buffer containing 5 mM EDC/sulfo-NHS (30 μL) was added and left there 
for 2h. The same experimental procedure was followed for the immobilization of the non-
specific antibodies (anti-human IgG) used as control. As alumina is well known to exhibit 
reduced protein adsorption, no blocking reagents are necessary to avoid unspecific 
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absorptions in complex matrixes such as cell culture medium (Espinoza-Castañeda et al., 
2015) or even whole blood (de la Escosura-Muñiz and Merkoçi, 2011). A thorough washing 
of the membranes before the electrochemical measurement allows to remove unspecific 
proteins present in the nanochannels. 
The design of the experimental set-up for the in situ cell culture/electrochemical detection 
(AAO membranes assembled to SPCEs) is detailed at the Supplementary Material. AAO 
nanoporous membranes were fixed onto the SPCEs by physical attachment, which consisted 
of placing the SPCEs onto a polyethylene terephthalate glycol-modified (PTEG) block 
(circular shape) and putting the membranes over the three-electrode surface. Then, a second 
circular PTEG block containing holes of the same size as the working area of the SPCEs was 
placed onto the AAO nanoporous membranes, with a red silicone (RS) insulating ring 
between them to avoid liquid leakage. Finally, the carousel-like system was fixed with a 
screw. Different materials were evaluated for building such set-up so as to find the optimum 
one which allows the cells to normally grow, without exerting any toxic effect (see materials 
optimization at the Supplementary Material). 
Finally, 1.5 mL of the desired amount of cells were placed on the AAO nanoporous 
membranes there and incubated at 37 °C in humidified atmosphere with 5% CO2 during a 
determined time. 
 
Electrochemical detection of PTHLH  
After washing with PBS buffer, the electrochemical cell containing the AAO nanoporous 
membrane was filled with 200 µL of a 10 µg/mL PBNPs suspension. A pre-treatment at -550 
mV was applied during 30s and immediately after, a differential pulse voltammetric (DPV) 
scan from -550 mV to +700 mV (step potential 10 mV, modulation amplitude 50 mV) was 
applied resulting in an analytical signal due to oxidation of Prussian blue (PB) to Berlin green 
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(BG) at approximately +500 mV, whose peak current is chosen as analytical signal. The 
measurements were carried out at room temperature under non- stirring conditions. 
Preliminary studies for i) the evaluation of the ability of the developed sensing system for the 
determination of PTHLH in a complex matrix such as the cell culture medium and ii) building 
the calibration plot for PTHLH determination were also performed. The medium was 
extracted from the cell culture and placed in Eppendorf tubes where different quantities of 
standard solutions of PTHLH were spiked. After that, 50 µL of this solution were placed onto 
the membranes (with the anti-PTHLH antibody previously immobilized) assembled with the 
SPCEs (set-up described at the Supplementary Material) and incubated during 2 h at room 
temperature. 
 
Cell transfection procedure 
Cell transfections were performed in two steps. First, 24000 HaCaT cells were cultured for 
20h onto the AAO nanoporous membranes assembled with the SPCE electrode (set-up 
described at the Supplementary Material). Then cells were exposed to a mixture of 0.25 L of 
20 M siRNA solution and different amounts of DharmaFECTTM solution (0.6 L and 0.3 L 
for the “high” and “low” amounts, respectively, according to the manufacturer’s indications) 
for 28h before collecting media for PTHLH analyses. “Blank” assays were performed 
following the same experimental procedure using cell culture medium instead of siRNA. 
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3. RESULTS AND DISCUSSION 
3.1. Cell growth onto AAO nanoporous membranes  
Initially, the ability of the cells to adhere and grow onto AAO nanoporous membranes was 
evaluated.  As shown at Figure 2, both neuroblastoma cells (SK-N-AS) and immortalized 
human keratinocytes (HaCaT cells) adhered and grew well onto these membranes (a and c 
respectively) showing a similar morphology to those grown onto standard culture flasks (b 




Figure 2. Optical microscope images (top view) of SK-N-AS (a,b) and HaCaT (c,d) cells 
seeded onto AAO nanoporous membranes (20 nm pore sized) (up) or in regular cell culture 
flasks (down) and allowed to grow for 48h. 
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Scanning electron microscopy (SEM) analysis was also used for a more accurate evaluation of 
the cultured cells on the membranes. As shown in Figure 3, cells adhered well onto the 
membranes, keeping the nanochannels free. This allows for the secreted PTHLH to enter the 




Figure 3. Scanning electrochemical microscope (SEM) images (top view) of SK-N-AS (a) 





 - 12 - 
3.2. Electrochemical detection of PTHLH in cell culture medium  
The ability of our system to specifically detect and quantify PTHLH in the complex matrix of 
the cell culture medium was first evaluated. Standard solutions of PTHLH were spiked in 
such a medium as detailed in the Experimental Section. The sensing principle, previously 
optimized by our group (Espinoza-Castañeda et al. 2015), is schematized at Figure 1 (right) 
and in the cartoon shown at Figure 4a. The immunocomplex formation inside the pores 
produces a partial blockage in the diffusion of the Prussian blue nanoparticles (PBNPs) (red-
ox indicator) through the nanoporous membranes to the electrochemical transducer surface, 
which results in a decrease in the voltammetric signal of oxidation of Prussian blue to Berlin 
green at approx. +500 mV which is chosen as analytical signal. As shown in Figure 4a, the 
analytical signal decreases by increasing spiked PTHLH concentration in the range 0 - 500 
ng/mL. Both parameters are adjusted to a logarithmic relationship within that range, with a 
correlation coefficient of 0.993, according to the following equation: 
ip (nA) = -0.569 [spiked PTHLH] (ng/mL) + 423 (Equation 1) 
The method shows a reproducibility (RSD) of 7 % (n= 3) for a PTHLH concentration of 100 
ng/mL. A limit of detection (LOD, calculated as the analyte concentration giving a signal 
equal to the blank signal + three times its standard deviation) of 55 ng/mL of PTHLH is 
estimated. These results are similar to those previously obtained in PBS buffer medium 
(Espinoza-Castañeda et al., 2015), suggesting that the matrix of the cell culture medium is not 
affecting the biosensing response, probably thanks to the filtering effect of the membranes 
which allows removing of interferences that could affect the analytical signal. These results 
are also in agreement with the obtained by lateral-flow immunoassays and Western blot 
analysis (Chamorro-García et al., 2016). Although immunoradiometric assays (IRMA) 
showed better sensitivity for PTHLH detection (LOD at pg/mL levels) (Fraser et al., 1993; 
Pandian et al., 1992), our method is able to monitor the levels secreted by cells at the basal 
state (typically ranging from ng/mL tog/mL) avoiding the problems related to the half-life 
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of the isotope, the potential hazard of radioactivity and the strict requirements needed to 
implement these procedures. 
The linear relationship (calibration plot) obtained was later used for the estimation of PTHLH 















































































Figure 4. In situ quantitation of PTHLH in cell culture media obtained from human cells 
grown onto AAO nanoporous membranes. (a) Scheme of the sensing principle together with 
differential pulse voltammograms (DPVs) obtained following the experimental procedure 
detailed in the Experimental Section for increasing concentrations of PTHLH (0, 200 and 500 
ng/mL, from up to down). PBNPs concentration: 10 µg/mL, Step potential: 10 mV, 
modulation amplitude 50 mV. The graph shows the analytical signals obtained for increasing 
spiked PTHLH concentrations (0 - 500 ng/mL) in cell culture medium. (b) Effect of total 
number of seeded cells and incubation time on the analytical signal for SK-N-AS (up) and 
HaCaT cells (down). “Control” assays were carried out by using membranes modified with 
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3.3. In situ PTHLH secretion evaluation in cell cultures on AAO nanoporous membranes 
As stated before, two human cell lines, a neuroblastoma cell line (SK-N-AS) and 
immortalized keratinocytes (HaCaT) as a control of high PTHLH production, were cultured 
onto AAO nanoporous membranes using the set-up described at the Supplementary Material. 
Secreted PTHLH was electrically monitored through the nanochannel blockage upon the 
immunocomplex formation inside the channels (Figure 1, right), following the procedure 
detailed in the Experimental Section. 
The effect of the total number of cells seeded and incubation time on the secreted PTHLH 
levels were evaluated. Two different cell numbers (24000 and 4800) and incubation times 
ranging from 3h to 48h were evaluated. “0h” time corresponds to measurements performed 
right after plating the cells, without allowing them to adhere and grow. “Control” assays were 
carried out by using membranes modified with unspecific anti-human IgG. As shown in 
Figure 4b, secreted PTHLH is detected in both cell lines with higher values being observed in 
the presence of higher number of seeded cells and upon longer incubation times. The results 
obtained for the “Control” assays demonstrate the specificity of the system, ruling out 
unspecific signals.   
Values of secreted PTHLH (extrapolated from Equation 1) are shown at Table 1. Levels 
range from approximately 60 to 400 ng/mL depending on cell type, number of seeded cells 
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Table 1. Estimated values of secreted PTHLH (extrapolated from Equation 1) for different 
cells amount and incubation time.  
 
 
3.4. Cell transfection studies: inhibition of PTHLH secretion by siRNA 
In order to further evaluate the specificity of our method, PTHLH secretion was quantified 
following transient silencing of PTHLH gene expression. This was conducted by means of 
small interfering RNA (siRNA). Transfection of eukaryotic cells is the process of inserting 
plasmid DNA or RNA into them. As pure genetic material would not naturally be transported 
into cells, an efficient transfection method with a transfection reagent is used as an  easy, cost-
effective, and efficient method for introducing foreign genetic material into cells. In our 
experiments, HaCaT cells (chosen for the demonstration of the proof-of-concept) were 
transfected with a small interfering RNA (siRNA) that specifically downregulates PTHLH 
messenger RNA (Figure 5a). Two different amounts of transfection reagent were evaluated, 
while no siRNA and non-targeting siRNA (siRNA-NT) were also assayed as blank and 
control respectively. As shown at the Supplementary Material (Supplementary Fig SM6), 
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upon transient transfection with a specific siRNA, a significant reduction of PHTLH mRNA 
was achieved in both SK-N-AS and HaCaT cells when compared to a siRNA-NT. Then, the 
inhibition of PTHLH production was in situ electrically monitored in cells showing normal or 
decreased levels of PTHLH mRNA expression. Voltammetric signals obtained under the 
different conditions assayed are shown in Figure 5b. The graph shows a summary of results 
in terms of % of signal inhibition, taking as reference the signal obtained for 24000 HaCaT 
cells cultured for 48h. A great inhibition of the analytical signal (close to 80%) was observed 
in cells with decreased expression of PTHLH mRNA following transfection with a high 
concentration of the transfection reagent. However, under these experimental conditions, a 
quite relevant signal inhibition was also observed for the blank (no siRNA) and for the control 
(siRNA-NT) (blue columns), thus suggesting  that high doses of transfection reagent are 
likely toxic and reduce cell viability. Conversely, in the presence of lower doses of 
transfection reagent (red columns), an important signal inhibition of PTHLH production is 
recorded in cells transfected with the specific siRNA (approx. 70%), while such inhibition is 
not significant for neither the blank nor the control. These results show that, under such 
conditions, we are able to successfully monitor the specific inhibition of PTHLH secretion 
upon PTHLH downregulation promoted by a specific PTHLH siRNA. It has been previously 
described that inhibition of PTHLH secretion can reduce tumor cell proliferation, survival and 
invasiveness. Thus, our system provides a potentially useful tool for the evaluation of 
therapies aimed at reducing PTHLH secretion.  Moreover, our method might be useful as well 
in the screening of drugs that regulate PTHLH production, and could be further applied to 
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Figure 5. Inhibition of PTHLH secretion by siRNA. (a) Schematic illustration of cell 
transfection process with small interfering RNA (siRNA) and a transfection reagent 
(DharmaFECTTM) which inhibits PTHLH mRNA expression. (b) DPVs obtained for  HaCaT 
cells (24000 cells, 20h growth) incubated for 28h with siRNA combined with a high (-a-) and 
low (-b-) amount of DharmaFECTTM  and with a non-targeting siRNA (siRNA-NT) combined 
with a high (-c-) and low (-d-) amount of DharmaFECTTM. Graph shows a summary of results 
in terms of % of signal inhibition, considering as reference the signal obtained for 24000 
HaCaT cells cultured during 48h. “No siRNA” corresponds to assays performed without 
siRNA (blank). DharmaFECTTM concentrations: 0.6 L/well (high, blue columns) and 0.3 





 - 18 - 
4. CONCLUSIONS 
Our present data show that anodic aluminum oxide (AAO) nanoporous membranes can be 
successfully used to in situ quantify PTHLH secretion from neuroblastoma (SK-N-AS) and 
keratinocytes (HaCaT) cell lines. Normal cell morphology, viability and growth onto these 
membranes have been shown by means of optical and electronic microscopy. PTHLH has 
been detected at levels as low as 55 ng/mL by the electrical monitoring of nanochannels 
blockage upon the formation of the immunocomplex with specific antibodies, using PBNPs as 
red-ox indicators. These results are in agreement with those previously obtained in buffer 
medium (Espinoza-Castañeda et al., 2015), suggesting that the matrix of the cell culture 
medium is not affecting the biosensing response. Although not reaching the high sensitivity of 
immunoradiometric assays (IRMA) for PTHLH detection (LOD at pg/mL levels) (Fraser et 
al., 1993; Pandian et al., 1992), our method is able to monitor the levels secreted by cells at 
the basal state (typically ranging from ng/mL tog/mL) overcoming the drawbacks of IRMA 
related to the half-life of the isotope, the potential hazard of radioactivity and the strict 
requirements needed to implement such procedures. Secreted PTHLH levels ranging from 
approximately 60 to 400 ng/mL have been detected depending on cell type, number of seeded 
cells and incubation time. These findings are also in line with the obtained by lateral-flow 
immunoassays and Western blot analysis (Chamorro-García et al., 2016).  
Therefore, in all, these results show that our method is a valid tool for in situ monitoring of 
PTHLH secretion, thus providing a new tool to evaluate PTHLH function and regulation in 
vitro. The proof-of-concept of such potentiality was provided by detecting reduced PTHLH 
secretion upon cell transfection with a specific small interfering RNA (siRNA). Such siRNA 
is able to interfere in the expression of the gene responsible for PTHLH production, being the 
inhibition of PTHLH production in situ electrically monitored. This method holds great 
potential for the screening of drugs that regulate PTHLH secretion and could be extended to 
other secreted protein as well. 
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